Botulinum toxin A treatment for contouring of the lower leg

Journal of Dermatological Treatment

Volumn 17, Issue 4, 2006, Pages 250-254

  Han, Kwang Ho ^a   Joo, Young Hyun ^b   Moon, Sang Eun ^b   Kim, Kyu Han ^b  

^a Chungdam LJH Skin Clinic   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Botox; Botulinum; Calf; Gastrocnemius

Indexed keywords

BOTULINUM TOXIN A; EMLA;

ADULT; ARTICLE; BODY POSITION; CASE REPORT; CLINICAL FEATURE; CONCENTRATION RESPONSE; ECCHYMOSIS; FEMALE; GASTROCNEMIUS MUSCLE; HUMAN; INJECTION SITE REACTION; LOWER LEG; MUSCLE HYPERTROPHY; MYALGIA; NEURECTOMY; PRIORITY JOURNAL; VISUAL ANALOG SCALE;

ADULT; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; HYPERTROPHY; LEG; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS;

EID: 33748693290     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600899070     Document Type: Article

References (20)

1. Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol. 1995;46:83-96.
2. Borodic GE, Ferrante RJ, Pearce LB, Alderson K. Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p. 119.
3. Moore AP, Wood GD. The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg. 1994;32:26-8.
4. Smyth AG. Botulinum toxin treatment in bilateral masseteric hypertrophy. Br J Oral Maxillofac Surg. 1994;32:29-33.
5. Von Lindern JJ, Niederhagen B, Appel T, Berge S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg. 2001;107:327-32.
6. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg. 2001;54:197-200.
7. Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for the contouring of the lower face. Dermatol Surg. 2003;29:477-83.
8. Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29:484-9.
9. Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg. 2005;31:502-8.
10. Kim IG, Hwang SH, Lew JM, Lee HY. Endoscope-assisted calf reduction in Orientals. Plast Reconstr Surg. 2000;106: 713-18.
11. Schuman M. Some Korean women go to great lengths to show a little leg. Tired of their thick calves, they find surgical solution. Wall Street Journal. February 21, 2001.
12. Seo KI, Hwang JH, Eun HC. Treatment of calf hypertrophy with botulinum toxin [In Korean]. Kor J Dermatol. 2002;40:S69.
13. Lee HJ, Lee DW, Park YH, Cha MK, Kim HS, Ha SJ. Botulinum toxin A for aesthetic contouring of enlarged medial gastrocnemius muscle. Dermatol Surg. 2004;30: 867-71.
14. Lowe NJ. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Dermatol Surg. 1998;24:1216-18.
15. Aoki KR. Preclinical update on Botox-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol. 1999;6:S3-10.
16. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235: 197-9.
17. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol. 2003;21:476-80.
18. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comprehensive study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149:1041-5.
19. Le Louarn C. Botulinum toxin A and facial lines: the variable concentration. Aesthetic Plast Surg. 2001;25:73-84.
20. Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg. 2005;115:919-30.